Phase 3 N=133 Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
Bladder Cancer
Primary: Complete Response Rate at 3 Months — 39 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=43 Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
Urinary Tract Urothelial Carcinoma
Primary: Number of Participants With Complete Response at 3 Months — 26 Participants
Phase 2 N=43 BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
Muscle Invasive Bladder Cancer
Primary: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging…
N/A N=965 Comparison Study of Narrow Band Imaging Versus White Light Resection in Patients With Bladder Tumors/Cancer
Bladder Cancer
Primary: Number of Participants With Recurrence and Recurrence Rate at 1 Year Following Narrow Band Imaging and TURB (Arm A) Versus White Light Trans Urethral Resection of…
Phase 2 N=3 Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer (NMIBC)
Primary: Phase 1: Dose Limiting Toxicities (DLT) Following Intravesical Administration of ABI-009 — 0; 0; 0; 0 Participants
Phase 2 N=76 Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Bladder Cancer
Primary: Clinical Complete Response (CCR) Rate — 43 Percentage of participants
Phase 2 N=63 A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
Bladder Cancer · Urothelial Carcinoma · Urothelial Carcinoma Bladder
Primary: Complete Response (CR) Rate for UGN-102 Treatment — 65.1 percentage of patients
Phase 1 N=18 MK-3475/BCG in High Risk Superficial Bladder Cancer
Bladder Cancer
Primary: Number of Participants With Grade 3, 4, and 5 Treatment Related Adverse Events — 0; 4; 3; 6 Participants
Phase 2 N=15 Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Bladder Cancer Cell Transitional · Non-Muscle Invasive Bladder Cancer · Bladder Cancer
Primary: Part 1: Maximum Tolerated Dose or Maximum Deliverable Dose (MDD) — NA; 360 mg
Phase 3 N=82 The Bladder Instillation Comparison Study
Urinary Bladder Neoplasms
Primary: Number of Participants Without Grade ≥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03 — 15; 14; 20 Participants
Phase 2 N=172 Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Recurrent Bladder Urothelial Carcinoma · Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 · Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7
Primary: Complete Response (CR) Rate in the Subset of Patients With Carcinoma in Situ (CIS) — 27 percentage of participants
Phase 1 N=43 Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Bladder Cancer
Primary: Grade 3 or Higher Treatment Related Adverse Events as Assessed by CTCAE V5.0 — 0; 0.07 proportion of participants
Phase 1 N=12 Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
Urinary Bladder Neoplasms
Primary: Number of Grades 1-5 Adverse Events — 12; 3; 15; 9 adverse events
Phase 3 N=114 A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
Bladder Cancer · Bladder Tumor · Muscle-Invasive Bladder Cancer
Primary: Pathologic Complete Response (pCR) Rate- Nivolumab + Bempegaldesleukin Compared to Standard of Care — 10.8; 2.5 Percentage of participants
Phase 2 N=29 Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
Urothelial Carcinoma
Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects
Phase 2 N=15 Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
Bladder Cancer
Primary: Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion — 13 Participants
Phase 2 N=46 Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
Urinary Bladder Cancer · Bladder Cancer · Bladder Neoplasms
Primary: Treatment Schedule A: 12-Week Efficacy, Treatment Schedule B: 13-Week Efficacy — 40.9; 39.1 percentage of patients
Phase 2 N=2 Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer
Urothelial Carcinoma of the Bladder
Primary: Number of Participants With Adverse Events — 2 Participants
Phase 1 N=9 Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
Recurrent Bladder Carcinoma · Stage 0a Bladder Urothelial Carcinoma · Stage 0is Bladder Urothelial Carcinoma
Primary: Maximum Tolerated Dose (MTD) — 2 mg/kg Pembrolizumab
Phase 2 N=36 First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Primary: Median Overall Survival — 13.9 months
Phase 2 N=54 Dose Dense MVAC for Muscle Invasive Bladder Cancer
Muscle Invasive Bladder Cancer · High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Primary: Percentage of Participants With Complete Response at Cystectomy or Ureterectomy Following Preoperative Dose Dense MVAC — 38 percentage of total participants
Phase 3 N=8 Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
Bladder Cancer · Urothelial Carcinoma · Urothelial Carcinoma Bladder
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation, and TEAEs of Special Interest. — 8; 3; 2; 7…
Phase 2 N=18 Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer
Bladder Cancer
Primary: Proportion of Patients Receiving Complete Induction Course — 0.833 proportion of patients
N/A N=130 Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer
Muscle Invasive Bladder Cancer
Primary: Accuracy of the PET CT for Lymph Node Staging in Terms of Sensitivy Rate — 21 Participants
Phase 1 N=16 CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)
Non-muscle Invasive Bladder Cancer
Primary: Incidence of Dose-limiting Toxicities Treatment-related Adverse Events. — 9; 6 Participants
Phase 2 N=37 Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
Bladder Cancer
Primary: Percentage of Participants Free From Radical Cystectomy at 3 Years — 88.2 percentage of participants
Early Phase 1 N=15 Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer
Transitional Cell Carcinoma of Bladder · Superficial Bladder Cancer
Primary: Safety and Tolerability — 5; 2; 1; 1 Grade 1/2 event count (no grade 3+)
Phase 2 N=32 Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
Invasive Bladder Cancer
Primary: Proportion of Patients With Pathological Response — 26; 2 Participants
Phase 2 N=32 Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
Bladder Cancer
Primary: Percentage of Participants Without Recurrence (Recurrence-free Survival (RFS)) With Bacillus Calmette-Guerin (BCG) + PANVAC Compared With BCG Alone at 6 and 12 Months…
Phase 2 N=45 Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer
Bladder Urothelial Carcinoma In Situ · Recurrent Bladder Urothelial Carcinoma · Stage 0a Bladder Cancer AJCC v8
Primary: Trial Recruitment: Number of Participants Eligible, Enrolled, and Not Enrolled — 45; 0; 3; 2 Participants